Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD2820 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| AZD2820 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| AZD2820 | DRUG | Subcutaneous Injection in abdomen or Thigh |
| Placebo | DRUG | Subcutaneous Injection in abdomen or Thigh |
Inclusion Criteria: * Provision of signed and dated, written informed consent prior to any study specific procedures. * Healthy male subjects aged ≥20 - ≤45 years with suitable veins for cannulation or repeated venepuncture. * Male subjects should be willing to use barrier contraception ie, condoms...
AZD2820 is an investigational small molecule being studied in healthy volunteers. It was evaluated in a Phase 1 clinical trial to assess its safety, tolerability, and pharmacokinetics after single ascending doses. The study enrolled 90 healthy male participants in the United Kingdom.
AZD2820 is being developed by AstraZeneca PLC, a biopharmaceutical company listed on the stock exchange under the ticker AZN. The company conducted a Phase 1 clinical trial of this investigational small molecule in healthy volunteers.
AZD2820 is in Phase 1 clinical development. It has completed a Phase 1 trial that assessed safety, tolerability, and pharmacokinetics after single ascending doses in healthy volunteers. The drug is investigational and has not been approved for any use.
AZD2820 has one completed clinical trial, registered as NCT01332214, titled "To Assess the Safety, Tolerability and Pharmacokinetics of AZD2820 After Single Ascending Doses." This Phase 1 study enrolled 90 healthy male participants aged 20 years and older in the United Kingdom.
Yes, AZD2820 was studied in a placebo-controlled Phase 1 clinical trial. The trial was randomized and placebo-controlled, though it was not double-blind. The study enrolled 90 healthy male volunteers and has been completed.